雜志介紹

Current Cancer Drug Targets雜志介紹

《Current Cancer Drug Targets》是一本以English為主的未開放獲取國際優(yōu)秀期刊，中文名稱當(dāng)前的抗癌藥物靶點，本刊主要出版、報道醫(yī)學(xué)-ONCOLOGY領(lǐng)域的研究動態(tài)以及在該領(lǐng)域取得的各方面的經(jīng)驗和科研成果，介紹該領(lǐng)域有關(guān)本專業(yè)的最新進(jìn)展，探討行業(yè)發(fā)展的思路和方法，以促進(jìn)學(xué)術(shù)信息交流，提高行業(yè)發(fā)展。該刊已被國際權(quán)威數(shù)據(jù)庫SCIE收錄，為該領(lǐng)域相關(guān)學(xué)科的發(fā)展起到了良好的推動作用，也得到了本專業(yè)人員的廣泛認(rèn)可。該刊最新影響因子為2.3，最新CiteScore 指數(shù)為5.4。

本刊近期中國學(xué)者發(fā)表的論文主要有：

• Combined Immunotherapy and Targeted Therapies for Cancer Treatment: Recent Advances and Future Perspectives

  Author: Zhang, Yan; Li, Yafei; Fu, Qiuxia; Han, Zhiqiang; Wang, Daijie; Shinge, Shafiu A. Umar; Muluh, Tobias Achu; Lu, Xiaohong

• Phosphoserine Aminotransferase 1: A Metabolic Enzyme Target of Cancers

  Author: Yang, Xue; Li, Chaojie; Chen, Yuping

• Combinatorial Application of Papain and CD66B for Isolating Glioma-Associated Neutrophils

  Author: Xu, Xing; Yang, Yongchang; Liu, Yancheng; Ge, Xianglian; Yi, Tailong; Xie, Yang; Ning, Chunlan; Shen, Shengfu; Sun, Zengfeng; Zhang, Zhen; Zhai, Qiongli; Wang, Xiaoguang; Meng, Xianghui; Dong, Jun; Huang, Qiang; Yang, Xuejun; Li, Wenliang; Jin, Xun

• Polyphyllin VII as a Potential Drug for Targeting Stemness in Hepatocellular Cancer via STAT3 Signaling

  Author: Xu, Liuhang; Chen, Ziqi; Wang, Yangbin; Li, Yulin; Wang, Zhongyu; Li, Fangzhou; Xi, Xueyan

英文介紹

Current Cancer Drug Targets雜志英文介紹

Current Cancer Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular drug targets involved in cancer, e.g. disease specific proteins, receptors, enzymes and genes.

Current Cancer Drug Targets publishes original research articles, letters, reviews / mini-reviews, drug clinical trial studies and guest edited thematic issues written by leaders in the field covering a range of current topics on drug targets involved in cancer.

As the discovery, identification, characterization and validation of novel human drug targets for anti-cancer drug discovery continues to grow; this journal has become essential reading for all pharmaceutical scientists involved in drug discovery and development.